Regis Reveals New Potent Compound Capabilities at InformEx 2015
Regis Technologies announced it will unveil its new potent compound capabilities at InformEx 2015, Feb. 3-5.
Regis Technologies, a contract manufacturing organization (CMO), announced that Wayne Nowicki, director of business development for the company, unveiled the details of its Potent Compound Suite (PCS) at a press conference held on Feb. 3, 2015. An expansion to the company’s Morton Grove, Illinois facility will give the PCS the ability to provide for small molecule cGMP manufacturing of potent compounds up to about one kilogram per batch.
According to a press release, the project was designed and constructed based on existing potent-compound handling requirements. The facility needed to be specially equipped with isolators, laminar flow hoods, and local exhaust ventilation to minimize containment risks. After a facility redesign, including relocation of chemical storage and office construction of new offices, Regis worked with Flow Sciences, a design and manufacture containment solution for research and development laboratories, to manufacture the containment isolator.
According to Flow Sciences, its containment solutions protect operators from exposure to hazardous particulates and vapors while performing operations.
Sources:
PR WebRegisInformExFlow Sciences
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
In Wake of Trump Tariffs, Lilly Plans New US Pharmaceutical Manufacturing Sites
February 26th 2025Previous domestic capital expansion commitments since 2020 had been made in Research Triangle Park and Concord, both in North Carolina; Kenosha County, Wisconsin; Lebanon, Indiana; and Lilly’s home city of Indianapolis.
Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase
Published: February 26th 2025 | Updated: February 26th 2025While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.
